Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576683 | 1.00 | MEN1 (0.43) | MEN1KMT2ATDP1MAPK1MAPT | |
| SCHEMBL5360145 | 0.85 | MEN1 (0.41) | MEN1KMT2ATDP1MAPK1MAPT | |
| SCHEMBL5356941 | 0.84 | MEN1 (0.42) | MEN1KMT2AL3MBTL1OPRM1OPRD1 | |
| SCHEMBL14576381 | 0.84 | MEN1 (0.42) | MEN1KMT2AL3MBTL1OPRM1OPRD1 | |
| SCHEMBL5369809 | 0.84 | MEN1 (0.35) | MEN1KMT2ATDP1MAPK1MAPT | |
| SCHEMBL14575995 | 0.81 | MEN1 (0.34) | MEN1KMT2ATDP1MAPK1RXFP1 | |
| SCHEMBL5364344 | 0.78 | MEN1 (0.49) | MEN1KMT2ATDP1MAPK1MAPT | |
| SCHEMBL5360295 | 0.78 | MEN1 (0.49) | MEN1KMT2ATDP1MAPK1MAPT | |
| SCHEMBL14611691 | 0.78 | ADRB2 (0.38) | TDP1MAPK1MAPTKDM4EHTT | |
| SCHEMBL10489556 | 0.72 | SLC2A1 (0.49) | MEN1KMT2ATDP1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173139-B2 | Enantioselective 1,4-addition of aromatic nucleophiles to α,β-unsaturated aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20030236438-A1 | Enantioselective 1,4-addition of aromatic nucleophiles to alpha,beta-unsaturated aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236438-A1 | Enantioselective 1,4-addition of aromatic nucleophiles to alpha,beta-unsaturated aldehydes using chiral organic catalysts | NAT1, AOX1, ALDH7A1 | MEN1 4362/4885KMT2A 1979/4885TDP1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.